• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of combined tumor markers identified by proteomics in urothelial cancer

Research Project

Project/Area Number 16591593
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Urology
Research InstitutionThe Department of Urology, Facultyof Medicine, Shiga University of Medical Science

Principal Investigator

YOSHIKI Tatsuhiro  Shiga University of Medical Science, Faculty of Medicine, Associate Professor, 医学部, 助教授 (80230704)

Co-Investigator(Kenkyū-buntansha) WAKABAYASHI Yoshihiko  Shiga University of Medical Science, Faculty of Medicine, Assistant Professor, 医学部, 講師 (80191724)
KIM Chol-Jang  Shiga University of Medical Science, Faculty of Medicine, Assistant Professor, 医学部, 講師 (10204968)
NARITA Mitsuhiro  Shiga University of Medical Science, Faculty of Medicine, Assistant, 医学部, 助手 (00263046)
JOHNIN Kazuyoshi  Shiga University of Medical Science, Faculty of Medicine, Assistant, 医学部, 助手 (90324590)
Project Period (FY) 2004 – 2005
Project Status Completed (Fiscal Year 2005)
Budget Amount *help
¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 2005: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 2004: ¥2,000,000 (Direct Cost: ¥2,000,000)
KeywordsUrothelial cancer / Tumor marker / Proteomics
Research Abstract

Using proteomic analysis, we previously identified calreticulin(CRT) as a potentially useful urinary marker for bladder cancer. Now, we have also identified gamma -synuclein(SNCG) and a soluble isoform of catechol-o-methyltransferase(s-COMT) as novel candidates for tumor markers in bladder cancer, by means of proteomic analysis. In the process of establishing a superior tumor marker system, we investigated the diagnostic value of a combination assay of these three proteins. Voided urine samples were obtained from 112 bladder cancer and 230 control patients. Urinary CRT, SNCG, and s-COMT were measured as a combined marker by quantitative western blot analysis. Relative concentration of each protein was calculated and the diagnostic value of a concomitant examination of these markers was evaluated by receiver operator characteristic analysis. With the best diagnostic cutoff, the overall sensitivity of the combined markers was 76.8%(95% confidence interval, 69-81%) with a specificity of 77.4%(72-80%), while those of a single use of CRT were 71.4% and 77.8%, respectively. When evaluated in relation to tumor characteristics, such as grade, stage, size, and outcome of urinary cytology, the diagnostic capacity of the combined markers was equal to or better than that of CRT in all categories. Concomitant use of CRT, SNCG, and s-COMT had higher sensitivity for detection of bladder cancer than did single use of CRT. Our study suggests that use of this panel of markers will improve the diagnosis of bladder cancer and may allow the development of a protein microarray assay or multi-channel enzyme-linked immunosorbent assay.

Report

(3 results)
  • 2005 Annual Research Report   Final Research Report Summary
  • 2004 Annual Research Report
  • Research Products

    (2 results)

All 2004

All Journal Article (2 results)

  • [Journal Article] Diagnostic potential in bladder cancer of a panel of tumor markers (Calreticulin, gamma-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis2004

    • Author(s)
      Iwaki H, et al.
    • Journal Title

      Cancer Science 95

      Pages: 955-961

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma -synuclein, and catechol-o-methyltransferase) identified by proteomic analysis.2004

    • Author(s)
      Iwaki H, et al.
    • Journal Title

      Cancer Science 95

      Pages: 955-961

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2005 Final Research Report Summary

URL: 

Published: 2004-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi